Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI

Running, not enrolling · Phase 1/Phase 2 · Has a placebo group

Conditions studied: STEMI, STEMI (ST Elevation MI), STEMI - ST Elevation Myocardial Infarction (MI), Stent Implantation

In brief

Adults who have had an ST-elevation myocardial infarction and were treated with stent placement will receive an intravenous infusion of a monoclonal antibody in order to prevent further heart muscle damage. The goal is to learn if this treatment improves some measures of heart function and inflammation. The study treatment patients will be compared to patients who receive placebo (inactive treatment).

Key facts

Study ID: NCT06678074
Run by: Implicit Bioscience
People needed: 10
Starts: 2025-02-06
Expected to finish: 2026-09-01
Last updated by the study team: 2026-03-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Acute myocardial infarction with ST elevation at the J-point in two contiguous leads as determined by ECG.
TIMI grade 0 (no flow) or grade 1 (penetration without perfusion) of the culprit artery on initial coronary angiogram
Symptom onset prior to PCI of ≤12 hours
Planned to receive the local standard of care for treatment of their STEMI and follow up which must include percutaneous coronary intervention (PCI)
Ability to infuse study drug within 12 hours of PCI
Age ≥18 years, willing and able to provide written informed consent and to comply with the protocol (i.e., reporting of symptoms)
Capable of completing study visits
Females participating in the study must meet one of the following criteria:
Postmenopausal (postmenopausal females must have no menstrual bleeding for at least 1 year);
Surgically sterilized (e.g., hysterectomy, bilateral oophorectomy, or tubal ligation) for at least 6 months; or
If not postmenopausal, agree to use a double method of contraception, one of which is a barrier method (e.g., intrauterine device plus condom, spermicidal gel plus condom) until 30 days after the treatment
Males who have not had a vasectomy must use appropriate contraception methods (barrier or abstinence) until 30 days after treatment

You may not qualify if…

An individual fulfilling any of the following criteria is to be excluded from enrollment in the study:
Killip Classification for Heart Failure Class III (acute pulmonary edema) or IV (cardiogenic shock)
Severe aortic or mitral valve disease
Failure to reperfuse, vascular dissection, cardiac perforation, cardiac arrest, requirement for mechanical circulatory support, or acute respiratory failure requiring ventilatory support
Major hemodynamic instability or uncontrolled ventricular arrhythmias
Planned or conducted thrombolytic therapy for treatment of this STEMI event
Planned or conducted coronary artery bypass graft
Previous major vascular intervention within the last 4 weeks
Major surgery within the last 6 weeks
Evidence of an active gastrointestinal or urogenital bleeding
Recent (<14 days) use of immunosuppressive or anti-inflammatory drugs (including oral corticosteroids at a prednisone equivalent dose of ≥0.5 mg/kg/day but not including inhaled or low-dose oral corticosteroids, non-steroidal anti-inflammatory drugs, or colchicine).
Chronic inflammatory disorder (i.e., rheumatoid arthritis, systemic lupus erythematosus).
Active infection (of any type), including chronic/recurrent infectious disease (including HBV, HCV, and HIV/AIDS), but excluding HCV+ with undetectable plasma RNA.
Neutropenia (<1,500/mm3 or <1,000/mm3 in Black/African American patients).
Active malignancy, excluding carcinoma in situ [any location] or localized non-melanoma skin cancer
Participation in any study using an investigational drug or device within 30 days or within 5 half-lives of the investigational drug (whichever is longer) of entry into this study.
Life expectancy of less than 1 year due to non-cardiac pathology
History of allergic reaction to atibuclimab (IC14), any monoclonal antibody, or any other component used in the study (including contrast media)
Body weight >300 pounds (weight limit of the PET/CT table)
Known severe renal (creatinine clearance <30 mL/min) or hepatic insufficiency as well as alanine transaminase (ALT) elevation ≥ 3x upper limit of normal; isolated AST-elevation is not considered an exclusion criterion from study participation
Any clinically significant abnormality identified at the time of Screening that in the judgment of the Investigator, or any sub-Investigator would preclude safe completion of the study

Where it is running

Washington University School of Medicine — St Louis, Missouri, United States
University of Virginia — Charlottesville, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.